NCT00665743

Brief Summary

We will evaluate the bioavailability of naproxen 500 mg administered as three dfferent formulations.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
30

participants targeted

Target at P25-P50 for phase_1

Timeline
Completed

Started Mar 2008

Shorter than P25 for phase_1

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2008

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

April 23, 2008

Completed
1 day until next milestone

First Posted

Study publicly available on registry

April 24, 2008

Completed
1 month until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2008

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2008

Completed
Last Updated

June 10, 2008

Status Verified

June 1, 2008

Enrollment Period

3 months

First QC Date

April 23, 2008

Last Update Submit

June 9, 2008

Conditions

Outcome Measures

Primary Outcomes (1)

  • To assess and compare the pharmacokinetics and relative bioavailability of a single oral dose of naproxen 500 mg administered in 3 formulations

    72-hour PK

Secondary Outcomes (1)

  • To evaluate the safety of the 3 treatments

    entire study duration

Study Arms (3)

A

EXPERIMENTAL

PN400 (naproxen/esomeprazole)

Drug: PN400

B

ACTIVE COMPARATOR

naproxen 500 mg

Drug: naproxen

C

ACTIVE COMPARATOR

naproxen 500 mg

Drug: naproxen

Interventions

PN400DRUG

naproxen 500 mg /esomeprazole 20 mg

A

naproxen 500 mg tablet

B

Eligibility Criteria

Age18 Years - 55 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Unknown Facility

Austin, Texas, United States

Location

MeSH Terms

Conditions

Arthritis

Interventions

Naproxen

Condition Hierarchy (Ancestors)

Joint DiseasesMusculoskeletal Diseases

Intervention Hierarchy (Ancestors)

Naphthaleneacetic AcidsNaphthalenesPolycyclic Aromatic HydrocarbonsHydrocarbons, AromaticHydrocarbons, CyclicHydrocarbonsOrganic ChemicalsPolycyclic Compounds

Study Design

Study Type
interventional
Phase
phase 1
Allocation
RANDOMIZED
Masking
NONE
Purpose
BASIC SCIENCE
Intervention Model
CROSSOVER
Sponsor Type
INDUSTRY

Study Record Dates

First Submitted

April 23, 2008

First Posted

April 24, 2008

Study Start

March 1, 2008

Primary Completion

June 1, 2008

Study Completion

June 1, 2008

Last Updated

June 10, 2008

Record last verified: 2008-06

Locations